Stockreport

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic an...

iBio, Inc.  (IBIO) 
NASDAQ:AMEX Investor Relations: ir.ibioinc.com
PDF Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 d [Read more]